DUSP3

Summary

DUSP3 (dual specificity phosphatase 3, HGNC:3069) is a protein-coding gene on chromosome 17q21.31, encoding Dual specificity protein phosphatase 3 (P51452). Shows activity both for tyrosine-protein phosphate and serine-protein phosphate, but displays a strong preference toward phosphotyrosines.

The protein encoded by this gene is a member of the dual specificity protein phosphatase subfamily. These phosphatases inactivate their target kinases by dephosphorylating both the phosphoserine/threonine and phosphotyrosine residues. They negatively regulate members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), which are associated with cellular proliferation and differentiation. Different members of the family of dual specificity phosphatases show distinct substrate specificities for various MAP kinases, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli. This gene maps in a region that contains the BRCA1 locus which confers susceptibility to breast and ovarian cancer. Although DUSP3 is expressed in both breast and ovarian tissues, mutation screening in breast cancer pedigrees and in sporadic tumors was negative, leading to the conclusion that this gene is not BRCA1.

Source: NCBI Gene 1845 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 24 total
• GTEx eGene: eQTL in 21 tissues, sQTL in 13 (q < 0.05)
• Constraint (gnomAD): pLI 0.04 (LoF-tolerant), LOEUF 1.06 (unconstrained)
• MANE Select transcript: NM_004090

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3069
Approved symbol	DUSP3
Name	dual specificity phosphatase 3
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000108861
Ensembl biotype	protein_coding
OMIM	600183
Entrez	1845

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000226004

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 3: 1, TSL 5: 2

ENST00000226004, ENST00000590342, ENST00000590753, ENST00000590935, ENST00000591618, ENST00000861136, ENST00000949183, ENST00000983223, ENST00001106969, ENST00001117433, ENST00001142215

RefSeq mRNA: 1 — MANE Select: NM_004090 NM_004090

CCDS: CCDS11469

Canonical transcript exons

ENST00000226004 — 3 exons

Exon	Start	End
ENSE00000854206	43778800	43778977
ENSE00001292277	43766125	43769814
ENSE00003568193	43774712	43774938

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 98.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.1384 / max 297.3607, expressed in 1813 samples.

Highest expression (Bgee): skeletal muscle tissue of rectus abdominis, skeletal muscle tissue of biceps brachii, biceps brachii, saphenous vein, vastus lateralis.

Genetic regulation across tissues (GTEx eQTL / sQTL)

DUSP3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 21 tissues and its splicing (sQTL) in 13 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 34 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Whole Blood	eqtl	1.9e-21	+0.23	17:43773321:C:G
Muscle Skeletal	sqtl	2.2e-12	-1.05	17:43774624:T:C
Artery Tibial	sqtl	2.1e-11	+1.42	17:43774624:T:C
Cells Cultured fibroblasts	eqtl	5.1e-09	+0.31	17:43766891:G:C
Esophagus Mucosa	eqtl	1.6e-07	-0.15	17:43802259:C:T
Esophagus Gastroesophageal Junction	sqtl	7.8e-06	+1.43	17:43774624:T:C
Artery Aorta	sqtl	9.5e-06	+1.21	17:43774624:T:C
Muscle Skeletal	eqtl	1.2e-05	+0.13	17:43765224:A:G
Artery Coronary	sqtl	1.9e-04	+1.38	17:43774624:T:C
Esophagus Muscularis	sqtl	4.4e-04	+1.17	17:43776870:G:T
Colon Sigmoid	sqtl	8.6e-04	+1.28	17:43774624:T:C
Artery Tibial	eqtl	1.0e-03	-0.21	17:43835134:C:G
Thyroid	eqtl	3.8e-03	+0.12	17:43837458:C:T
Artery Aorta	eqtl	7.2e-03	+0.14	17:43814671:C:A
Pituitary	eqtl	7.4e-03	+0.22	17:43456911:C:T
Testis	sqtl	1.0e-02	+0.72	17:43720816:C:A
Skin Not Sun Exposed Suprapubic	eqtl	1.0e-02	-0.12	17:43768456:G:A
Brain Cerebellar Hemisphere	eqtl	1.1e-02	-0.33	17:43187992:G:A
Heart Atrial Appendage	sqtl	1.2e-02	-1.15	17:43776870:G:T
Nerve Tibial	eqtl	1.2e-02	+0.30	17:43952508:C:T

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
166277	44.6308	1812
166276	1.7228	1012
166272	0.4248	205
166273	0.3600	174

Top tissues by expression

showing 100 of 301 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.72	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.62	gold quality
biceps brachii	UBERON:0001507	98.34	gold quality
saphenous vein	UBERON:0007318	98.28	gold quality
vastus lateralis	UBERON:0001379	98.22	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.22	gold quality
skeletal muscle tissue	UBERON:0001134	98.20	gold quality
left ventricle myocardium	UBERON:0006566	98.20	gold quality
quadriceps femoris	UBERON:0001377	98.10	gold quality
cardiac ventricle	UBERON:0002082	98.08	gold quality
heart left ventricle	UBERON:0002084	98.08	gold quality
diaphragm	UBERON:0001103	97.97	gold quality
gastrocnemius	UBERON:0001388	97.86	gold quality
heart right ventricle	UBERON:0002080	97.83	gold quality
muscle tissue	UBERON:0002385	97.79	gold quality
muscle organ	UBERON:0001630	97.71	gold quality
skeletal muscle organ	UBERON:0014892	97.71	gold quality
apex of heart	UBERON:0002098	97.70	gold quality
myocardium	UBERON:0002349	97.70	gold quality
gluteal muscle	UBERON:0002000	97.66	gold quality
body of tongue	UBERON:0011876	97.60	gold quality
muscle of leg	UBERON:0001383	97.53	gold quality
heart	UBERON:0000948	97.37	gold quality
triceps brachii	UBERON:0001509	97.22	gold quality
deltoid	UBERON:0001476	97.17	gold quality
right coronary artery	UBERON:0001625	97.04	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.93	gold quality
cauda epididymis	UBERON:0004360	96.82	gold quality
cardiac atrium	UBERON:0002081	96.77	gold quality
right atrium auricular region	UBERON:0006631	96.72	gold quality
type B pancreatic cell	CL:0000169	96.71	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.68	gold quality
lower esophagus	UBERON:0013473	96.67	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.66	gold quality
renal medulla	UBERON:0000362	96.63	gold quality
orbitofrontal cortex	UBERON:0004167	96.56	gold quality
prefrontal cortex	UBERON:0000451	96.19	gold quality
coronary artery	UBERON:0001621	96.13	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.11	gold quality
dorsal root ganglion	UBERON:0000044	96.10	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.09	gold quality
frontal pole	UBERON:0002795	96.06	gold quality
left coronary artery	UBERON:0001626	95.98	gold quality
artery	UBERON:0001637	95.95	gold quality
popliteal artery	UBERON:0002250	95.92	gold quality
tibial artery	UBERON:0007610	95.92	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.88	gold quality
cardia of stomach	UBERON:0001162	95.84	gold quality
aorta	UBERON:0000947	95.81	gold quality
vena cava	UBERON:0004087	95.80	gold quality
urethra	UBERON:0000057	95.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.75	gold quality
adult mammalian kidney	UBERON:0000082	95.74	gold quality
tibialis anterior	UBERON:0001385	95.72	gold quality
pylorus	UBERON:0001166	95.70	gold quality
thoracic aorta	UBERON:0001515	95.66	gold quality
Brodmann (1909) area 46	UBERON:0006483	95.66	gold quality
ascending aorta	UBERON:0001496	95.63	gold quality
tongue	UBERON:0001723	95.56	gold quality
frontal cortex	UBERON:0001870	95.56	gold quality
substantia nigra pars compacta	UBERON:0001965	95.56	gold quality
superficial temporal artery	UBERON:0001614	95.55	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	95.54	gold quality
lower lobe of lung	UBERON:0008949	95.46	gold quality
cingulate cortex	UBERON:0003027	95.43	gold quality
olfactory bulb	UBERON:0002264	95.41	gold quality
nipple	UBERON:0002030	95.39	gold quality
smooth muscle tissue	UBERON:0001135	95.38	gold quality
right frontal lobe	UBERON:0002810	95.37	gold quality
anterior cingulate cortex	UBERON:0009835	95.36	gold quality
inferior olivary complex	UBERON:0002127	95.34	gold quality
pons	UBERON:0000988	95.20	gold quality
right lobe of liver	UBERON:0001114	95.17	gold quality
neocortex	UBERON:0001950	95.17	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.16	gold quality
parietal lobe	UBERON:0001872	95.14	gold quality
superior frontal gyrus	UBERON:0002661	95.10	gold quality
Brodmann (1909) area 10	UBERON:0013541	95.02	gold quality
descending thoracic aorta	UBERON:0002345	94.92	gold quality
cerebral cortex	UBERON:0000956	94.91	gold quality
trigeminal ganglion	UBERON:0001675	94.91	gold quality
islet of Langerhans	UBERON:0000006	94.88	gold quality
pharyngeal mucosa	UBERON:0000355	94.88	gold quality
amygdala	UBERON:0001876	94.87	gold quality
liver	UBERON:0002107	94.85	gold quality
temporal lobe	UBERON:0001871	94.80	gold quality
entorhinal cortex	UBERON:0002728	94.77	gold quality
lower esophagus mucosa	UBERON:0035834	94.77	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.76	gold quality
postcentral gyrus	UBERON:0002581	94.75	gold quality
lateral globus pallidus	UBERON:0002476	94.68	gold quality
sigmoid colon	UBERON:0001159	94.54	gold quality
medulla oblongata	UBERON:0001896	94.50	gold quality
superior vestibular nucleus	UBERON:0007227	94.39	gold quality
jejunum	UBERON:0002115	94.35	gold quality
telencephalon	UBERON:0001893	94.32	gold quality
cerebellar vermis	UBERON:0004720	94.25	gold quality
ventral tegmental area	UBERON:0002691	94.22	gold quality
hypothalamus	UBERON:0001898	94.21	gold quality
fundus of stomach	UBERON:0001160	94.17	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 74 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Skeletal muscle	tissue	245.3
Tongue	tissue	199.4
Corpus callosum	tissue	151.8
Spinal cord	tissue	135.9
Heart muscle	tissue	130.0
Cerebral cortex	tissue	115.1
Motor cortex	tissue	115.1
Somatosensory cortex	tissue	111.6
Midbrain	tissue	108.9
Occipital cortex	tissue	107.3
Medulla oblongata	tissue	106.2
Prefrontal cortex	tissue	102.6
Hippocampal formation	tissue	98.9
Entorhinal cortex	tissue	97.8
Temporal cortex	tissue	93.5
Insular cortex	tissue	93.3
Thalamus	tissue	93.2
Cingulate cortex	tissue	93.2
Retrosplenial cortex	tissue	91.7
Substantia nigra	tissue	91.2
Superior colliculi	tissue	85.0
Pons	tissue	84.5
Putamen	tissue	76.1
Postcentral gyrus	tissue	72.5
Seminal vesicle	tissue	68.7
Ventral pallidum	tissue	65.4
Locus coeruleus	tissue	63.3
Hippocampus	tissue	61.1
Amygdala	tissue	59.6
Liver	tissue	59.6
Smooth muscle	tissue	58.8
Periaqueductal gray	tissue	56.2
Hypothalamus	tissue	55.9
Septum	tissue	55.0
Kidney	tissue	53.0
Choroid plexus	tissue	52.5
Basal ganglia	tissue	51.9
Nucleus accumbens	tissue	46.7
Esophagus	tissue	45.4
Parathyroid gland	tissue	44.2
Prostate	tissue	42.1
Olfactory bulb	tissue	40.0
Urinary bladder	tissue	37.3
Lung	tissue	34.0
Adrenal gland	tissue	33.7
Adipose tissue	tissue	33.6
Vagina	tissue	32.3
Pancreas	tissue	32.1
Pituitary gland	tissue	32.0
Gallbladder	tissue	31.3
Cerebellum	tissue	30.3
Spleen	tissue	29.7
Endometrium 1	tissue	29.6
Placenta	tissue	29.5
Epididymis	tissue	29.4
Retina	tissue	28.5
Colon	tissue	28.2
Thyroid gland	tissue	26.2
Duodenum	tissue	26.2
Small intestine	tissue	25.8

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — White matter (151.8), Ventral spinal cord (135.9), Dorsal spinal cord (114.6), Dorsal hippocampus (98.9), Blood vessel (83.3).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting DUSP3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 167 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057

Functional genomics

gnomAD constraint: pLI 0.0402, LOEUF 1.06, missense Z 0.729 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000226004 — one region, missense o/e 0.83.

Literature-anchored findings (GeneRIF, showing 27)

• VHR, a Vaccinia virus VH1-related dual-specific protein phosphatase, is phosphorylated at Y138 by ZAP-70. (PMID:12447358)
• VHR is required for cell-cycle progression as it modulates MAP kinase activation in a cell-cycle phase-dependent manner. (PMID:16604064)
• deregulated expression of BRCA1-IRIS is likely to reduce dependence on normal physiological growth stimuli (PMID:17278098)
• Small dual-specificity phosphatase VHR selectively dephosphorylates tyrosine-phosphorylated interferon-alpha- and beta-activated transcription factor STAT5, leading to the subsequent inhibition of STAT5 function. (PMID:17785772)
• Results highlight the importance of a high intracellular Zn(2+) content and the VHR/ZAP-70/ERK1,2-associated pathways in the modulation of LNCaP prostate cancer cell growth. (PMID:18311544)
• VHR can be considered as a new marker for cancer progression in cervix carcinoma and potential new target for anticancer therapy (PMID:18505570)
• VHR has a direct role in the inhibition of JNK-dependent apoptosis in LNCaP cells and may therefore have a role in prostate cancer progression. (PMID:19010898)
• VHR expression enhances the signaling of ErbB receptors and may be involved in NSCLC pathogenesis. (PMID:21262974)
• Enteric commensal bacteria induce extracellular signal-regulated kinase pathway signaling via formyl peptide receptor-dependent redox modulation of dual specific phosphatase 3 (PMID:21921027)
• Proteins containing the class II motifs are efficient VHR substrates in vitro, suggesting that VHR may act on a novel class of yet unidentified Tyr(P) proteins in vivo. (PMID:23322772)
• we report the first successful site-specific incorporation of sulfotyrisine into VHR through the use of expanding genetic code (PMID:23918168)
• DUSP3 interacting partners are nucleolar proteins involved in processes related to DNA repair and senescence. (PMID:24245651)
• VHR can dimerize inside cells, and that VHR catalytic activity is reduced upon dimerization. (PMID:24798147)
• DUSP3 is a pro-angiogenic atypical dual-specificity phosphatase. (PMID:24886454)
• Data suggest levels of gene expression of both DUSP3 (dual specificity phosphatase 3) and PSME3 (proteasome activator subunit 3) are associated with susceptibility to Staphylococcus aureus infection/sepsis in humans and in mouse disease model. (PMID:24901344)
• Our results demonstrate that DUSP3 plays a key and nonredundant role as a regulator of innate immune responses (PMID:25876765)
• In the phosphatase-silenced cells, the normal bipolar spindle structure was restored by chemical inhibition of Erk1/2 and ectopic overexpression of Dusp3. We propose that at M phase Dusp3 keeps Erk1/2 activity in check to facilitate normal mitosis. (PMID:27423135)
• Nuclear HSP70 leads to enhancement of vaccinia H1-related phosphatase (VHR) activity via protein-protein interaction rather than its molecular chaperone activity, thereby suppressing excessive ERK activation. Downregulation of either VRK3 or HSP70 rendered cells vulnerable to glutamate-induced apoptosis. (PMID:27941812)
• The loss of DUSP3 activity markedly increases gamma radiation-induced DNA strand breaks, suggesting a potential novel role for DUSP3 in DNA repair. (PMID:28389334)
• In PTP1B and VHR, two new allosteric clusters were identified in each enzyme. (PMID:28625849)
• Data indicated that regulating non-receptor tyrosine kinase FAK and cell migration is a newly revealed function of VHR/DUSP3. (PMID:28759036)
• Study demonstrated that miR-1915-3p might promote the proliferation and metastasis of breast cancer by repression of DUSP3 and serum miR-1915-3p and miR-455-3p could serve as diagnostic and predictive biomarkers for breast cancer. (PMID:30048472)
• Allosteric Impact of the Variable Insert Loop in Vaccinia H1-Related (VHR) Phosphatase. (PMID:32348128)
• DUSP3 maintains genomic stability and cell proliferation by modulating NER pathway and cell cycle regulatory proteins. (PMID:32380926)
• Regulation of signal transducer and activator of transcription 3 activation by dual-specificity phosphatase 3. (PMID:32475380)
• The role of dual-specificity phosphatase 3 in melanocytic oncogenesis. (PMID:35899430)
• DUSP3 modulates IRES-dependent translation of mRNAs through dephosphorylation of the HNRNPC protein in cells under genotoxic stimulus. (PMID:38538536)

Cross-species orthologs

0 orthologs

Paralogs (31): DUSP13B (ENSG00000079393), DUSP12 (ENSG00000081721), SSH1 (ENSG00000084112), PTPMT1 (ENSG00000110536), DUSP16 (ENSG00000111266), EPM2A (ENSG00000112425), DUSP22 (ENSG00000112679), DUSP1 (ENSG00000120129), DUSP4 (ENSG00000120875), STYXL1 (ENSG00000127952), DUSP9 (ENSG00000130829), DUSP26 (ENSG00000133878), DUSP5 (ENSG00000138166), DUSP6 (ENSG00000139318), SSH2 (ENSG00000141298), DUSP10 (ENSG00000143507), DUSP15 (ENSG00000149599), DUSP2 (ENSG00000158050), KASH5 (ENSG00000161609), DUSP19 (ENSG00000162999), DUSP7 (ENSG00000164086), DUSP18 (ENSG00000167065), SSH3 (ENSG00000172830), DUSP8 (ENSG00000184545), DUSP28 (ENSG00000188542), DUSP29 (ENSG00000188716), DUSP21 (ENSG00000189037), STYX (ENSG00000198252), STYXL2 (ENSG00000198842), DUSP14 (ENSG00000276023), DUSP13A (ENSG00000293543)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1919599) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.

Mouse phenotype (MP)	Records
increased circulating insulin level	1
decreased hemoglobin content	1
increased circulating glycerol level	1
decreased lean body mass	1
abnormal humerus morphology	1
decreased circulating creatinine level	1
decreased angiogenesis	1
decreased grip strength	1
decreased red blood cell distribution width	1
decreased bone mineral content	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RD73	100.0%	Diamond
Bos taurus	Q2KJ36	99.2%	Diamond
Rattus norvegicus	Q63340	98.8%	Diamond
Mus musculus	Q91Z46	98.8%	Diamond
Pan troglodytes	P0C594	98.2%	Diamond
Xenopus laevis	Q4V7N3	97.8%	Diamond
Xenopus tropicalis	A4IHU7	92.3%	Diamond
Sus scrofa	P0C596	90.5%	Diamond
Takifugu rubripes	P0C599	89.0%	Diamond
Tetraodon nigroviridis	Q4RQD3	89.0%	Diamond
Monodelphis domestica	P0C593	86.4%	Diamond
Gasterosteus aculeatus	P0C5A0	82.9%	Diamond
Gallus gallus	P0C597	82.1%	Diamond
Anolis carolinensis	P0C598	81.9%	Diamond
Oryzias latipes	P0C5A1	80.9%	Diamond
Equus caballus	P0C592	78.5%	Diamond
Danio rerio	Q566R7	69.1%	Diamond
Callorhinchus milii	P0C5A2	68.5%	Diamond
Arabidopsis thaliana	Q9M8K7	64.0%	Diamond
Dictyostelium discoideum	Q55CS8	62.6%	Diamond
Saccharomyces cerevisiae S288C	P40479	52.7%	Diamond
Drosophila melanogaster	Q6NN85	50.9%	Diamond
Vaccinia virus WR	P07239	99.4%	Diamond
Vaccinia virus Copenhagen	P20495	99.4%	Diamond
Monkeypox virus	A0A7H0DN78	98.8%	Diamond
Orgyia pseudotsugata multiple nucleopolyhedrovirus	O10273	53.8%	Diamond
Betaentomopoxvirus amoorei	Q9EMX1	51.9%	Diamond
Invertebrate iridescent virus 6	O55737	49.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
LINC02594	ncRNA	105371786
MEOX1	protein-coding	4222
SOST	protein-coding	50964
CFAP97D1	protein-coding	284067
MPP3	protein-coding	4356
CD300LG	protein-coding	146894

Protein

Protein identifiers

Dual specificity protein phosphatase 3 — P51452 (reviewed: P51452)

Alternative names: Dual specificity protein phosphatase VHR, Vaccinia H1-related phosphatase

All UniProt accessions (4): P51452, K7ELG5, K7EPK5, K7ES89

UniProt curated annotations — full annotation on UniProt →

Function. Shows activity both for tyrosine-protein phosphate and serine-protein phosphate, but displays a strong preference toward phosphotyrosines. Specifically dephosphorylates and inactivates ERK1 and ERK2.

Subunit / interactions. Microtubule inner protein component of sperm flagellar doublet microtubules. Interacts with VRK3; this interaction activates DUSP3 phosphatase activity.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Flagellum axoneme.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class dual specificity subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P51452-1	1	yes
P51452-2	2

RefSeq proteins (1): NP_004081* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000340	Dual-sp_phosphatase_cat-dom	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR016130	Tyr_Pase_AS	Active_site
IPR020405	Atypical_DUSP_subfamA	Family
IPR020422	TYR_PHOSPHATASE_DUAL_dom	Domain
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily

Pfam: PF00782

Enzyme classification (BRENDA)

• EC 3.1.3.16 — protein-serine/threonine phosphatase (BRENDA: 92 organisms, 641 substrates, 468 inhibitors, 127 Km, 67 kcat entries)
• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

129 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.023–0.862	22
P-NITROPHENYL PHOSPHATE	0.0024–10	20
4-NITROPHENYL PHOSPHATE	0.0028–12.7	13
DADEPYLIPQQG	0.0003–0.1	12
P-NITROPHENYL PHOSPHATE	3–200	11
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
RRAPTVA	0.058–1.954	4
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
PHOSPHOCASEIN	0.0001–0.002	3
PHOSPHOHISTONE	0.0023–0.0723	3

Catalyzed reactions (Rhea)

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)
• O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + phosphate (RHEA:20629)
• O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + phosphate (RHEA:47004)

UniProt features (24 total): helix 10, strand 8, turn 2, chain 1, domain 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

9 structures by resolution:

PDB	Title	Method	Resolution (Å)
8TK6	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) in apo form	X-RAY DIFFRACTION	1.65
8TK2	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with …	X-RAY DIFFRACTION	1.7
8TK4	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with phosphate	X-RAY DIFFRACTION	1.8
3F81	Interaction of VHR with SA3	X-RAY DIFFRACTION	1.9
8TK5	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with HEPES	X-RAY DIFFRACTION	1.9
9DJ9	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) in distinct apo form	X-RAY DIFFRACTION	1.92
8TK3	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) having oxidized catalytic cysteine …	X-RAY DIFFRACTION	2
1VHR	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE	X-RAY DIFFRACTION	2.1
1J4X	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE C124S MUTANT-PEPTIDE COMPLEX	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51452-F1	96.10	0.93

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Predicted intracellular proteins, Plasma proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; cytosol

Antibody reliability (HPA): IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
124	phosphocysteine intermediate

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 30; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

30 pathways:

ID	Pathway	Evidence
R-HSA-202670	ERKs are inactivated	curated
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-198753	ERK/MAPK targets	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—
R-HSA-448424	Interleukin-17 signaling	—
R-HSA-450294	MAP kinase activation	—
R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	—
R-HSA-975871	MyD88 cascade initiated on plasma membrane	—
R-HSA-975155	MyD88 dependent cascade initiated on endosome	—
R-HSA-166166	MyD88-independent TLR4 cascade	—
R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	—
R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	—
R-HSA-162582	Signal Transduction	—
R-HSA-449147	Signaling by Interleukins	—
R-HSA-187037	Signaling by NTRK1 (TRKA)	—
R-HSA-166520	Signaling by NTRKs	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—
R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	—
R-HSA-937061	TRIF (TICAM1)-mediated TLR4 signaling	—
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	—
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	—
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	—
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	—
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	—
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	—
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	—
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	—
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	—
R-HSA-168898	Toll-like Receptor Cascades	—

MSigDB gene sets: 344 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_ERK1_AND_ERK2_CASCADE, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, KEGG_MAPK_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_FOCAL_ADHESION_ASSEMBLY, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP

GO Biological Process (16): dephosphorylation (GO:0016311), negative regulation of cell migration (GO:0030336), peptidyl-tyrosine dephosphorylation (GO:0035335), negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059), negative regulation of MAPK cascade (GO:0043409), positive regulation of mitotic cell cycle (GO:0045931), negative regulation of JNK cascade (GO:0046329), negative regulation of T cell receptor signaling pathway (GO:0050860), negative regulation of T cell activation (GO:0050868), negative regulation of chemotaxis (GO:0050922), regulation of focal adhesion assembly (GO:0051893), negative regulation of ERK1 and ERK2 cascade (GO:0070373), cellular response to epidermal growth factor stimulus (GO:0071364), positive regulation of focal adhesion disassembly (GO:0120183), protein dephosphorylation (GO:0006470), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (13): protein serine/threonine phosphatase activity (GO:0004722), protein tyrosine phosphatase activity (GO:0004725), cytoskeletal protein binding (GO:0008092), protein tyrosine/serine/threonine phosphatase activity (GO:0008138), phosphatase activity (GO:0016791), protein kinase binding (GO:0019901), receptor signaling protein tyrosine kinase inhibitor activity (GO:0030294), receptor tyrosine kinase binding (GO:0030971), MAP kinase phosphatase activity (GO:0033549), protein tyrosine kinase binding (GO:1990782), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (5): immunological synapse (GO:0001772), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

11 top-level categories:

Category	Pathways
Toll-like Receptor Cascades	7
Immune System	2
Toll Like Receptor 4 (TLR4) Cascade	2
Toll Like Receptor 2 (TLR2) Cascade	2
ERK/MAPK targets	1
Toll Like Receptor TLR1:TLR2 Cascade	1
Toll Like Receptor TLR6:TLR2 Cascade	1
Signaling by Receptor Tyrosine Kinases	1
Innate Immune System	1
Signaling by NTRKs	1
Signaling by NTRK1 (TRKA)	1

GO top-level categories

showing 60 of 63 GO namespaces:

Category	Terms
phosphoprotein phosphatase activity	4
cellular anatomical structure	4
negative regulation of MAPK cascade	2
phosphate-containing compound metabolic process	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
protein dephosphorylation	1
epidermal growth factor receptor signaling pathway	1
regulation of epidermal growth factor receptor signaling pathway	1
negative regulation of ERBB signaling pathway	1
MAPK cascade	1
regulation of MAPK cascade	1
negative regulation of intracellular signal transduction	1
mitotic cell cycle	1
regulation of mitotic cell cycle	1
positive regulation of cell cycle	1
JNK cascade	1
regulation of JNK cascade	1
T cell receptor signaling pathway	1
regulation of T cell receptor signaling pathway	1
negative regulation of antigen receptor-mediated signaling pathway	1
T cell activation	1
regulation of T cell activation	1
negative regulation of lymphocyte activation	1
negative regulation of leukocyte cell-cell adhesion	1
chemotaxis	1
negative regulation of response to external stimulus	1
negative regulation of locomotion	1
regulation of chemotaxis	1
regulation of cell-matrix adhesion	1
focal adhesion assembly	1
regulation of cell-substrate junction assembly	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
response to epidermal growth factor	1
cellular response to growth factor stimulus	1
focal adhesion disassembly	1
regulation of focal adhesion disassembly	1
positive regulation of cell-substrate junction organization	1
dephosphorylation	1
protein modification process	1
signal transduction	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
protein binding	1
phosphoric ester hydrolase activity	1
kinase binding	1
protein tyrosine kinase inhibitor activity	1
signaling receptor binding	1
protein tyrosine kinase binding	1
protein kinase binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
plasma membrane	1
intracellular membrane-bounded organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 25 of 34 annotations. The rest are phylogenetic / computational / electronic (IEA).

25 experimentally-supported GO terms:

GO term	NS	Evidence
cellular response to epidermal growth factor stimulus	BP	mutant phenotype
dephosphorylation	BP	direct assay
negative regulation of ERK1 and ERK2 cascade	BP	direct assay
negative regulation of JNK cascade	BP	direct assay
negative regulation of MAPK cascade	BP	mutant phenotype
negative regulation of T cell activation	BP	direct assay
negative regulation of T cell receptor signaling pathway	BP	direct assay
negative regulation of cell migration	BP	mutant phenotype
negative regulation of chemotaxis	BP	mutant phenotype
peptidyl-tyrosine dephosphorylation	BP	direct assay
positive regulation of focal adhesion disassembly	BP	mutant phenotype
positive regulation of mitotic cell cycle	BP	mutant phenotype
regulation of focal adhesion assembly	BP	mutant phenotype
cytosol	CC	direct assay
immunological synapse	CC	direct assay
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
MAP kinase phosphatase activity	MF	mutant phenotype
cytoskeletal protein binding	MF	physical interaction
phosphatase activity	MF	direct assay
protein kinase binding	MF	direct assay
protein tyrosine kinase binding	MF	physical interaction
protein tyrosine phosphatase activity	MF	direct assay
protein tyrosine/serine/threonine phosphatase activity	MF	direct assay
receptor tyrosine kinase binding	MF	physical interaction

Protein interactions and networks

STRING

showing 16 of 1,219 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DUSP3	PTS	Q03393	675
DUSP3	PTPN1	P18031	659
DUSP3	EPM2A	O95278	625
DUSP3	PTPN7	P35236	610
DUSP3	DUSP23	Q9BVJ7	609
DUSP3	PTPRA	P18433	571
DUSP3	VRK3	Q8IV63	569
DUSP3	ZAP70	P43403	561
DUSP3	GBP5	Q96PP8	550
DUSP3	KDM2A	Q9Y2K7	522
DUSP3	PTPN2	P17706	509
DUSP3	MAPK1	P28482	496
DUSP3	NFATC2	Q13469	486
DUSP3	ACP1	P24666	484
DUSP3	LHFPL2	Q6ZUX7	470
DUSP3	CDC14A	Q9UNH5	470

IntAct

Human interaction partners of DUSP3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

11 partners by confidence:

Partner	Interaction type	MIscore	Records
MEOX1	physical association	0.560	3
ERLIN1	association	0.530	5
MAPK1	dephosphorylation reaction	0.440	1
MAPK3	dephosphorylation reaction	0.440	1
TUFM	physical association	0.400	1
BNIP3L	physical association	0.370	1
CASK	physical association	0.370	1
NEUROD1	physical association	0.370	1
POU3F1	association	0.350	1
HLA-B	physical association	0.000	1
MCC	physical association	0.000	1

BioGRID (91 interactions; top human partners by supporting records): AGO2 (Affinity Capture-RNA; 2 records), ARL6IP6 (Affinity Capture-MS; 2 records), C16orf71 (Affinity Capture-MS; 2 records), ERLIN1 (Affinity Capture-MS; 2 records), ERLIN2 (Affinity Capture-MS; 2 records), MAPK1 (Biochemical Activity; 2 records), MAPK3 (Biochemical Activity; 2 records), APP (Reconstituted Complex), ARF5 (Affinity Capture-MS), BAD (Proximity Label-MS), BNIP3L (Two-hybrid), C15orf57 (Affinity Capture-MS), C6orf120 (Affinity Capture-MS), CALCOCO2 (Proximity Label-MS), CARTPT (Affinity Capture-MS)

SIGNOR signaling

showing 14 of 16 signaling interactions:

A	Effect	B	Mechanism
DUSP3	“down-regulates activity”	MAPK3	dephosphorylation
TYK2	up-regulates	DUSP3	phosphorylation
DUSP3	“down-regulates activity”	EGFR	dephosphorylation
DUSP3	“down-regulates activity”	ERBB2	dephosphorylation
DUSP3	“down-regulates activity”	NPM1	dephosphorylation
DUSP3	“down-regulates activity”	PTK2	dephosphorylation
DUSP3	“down-regulates activity”	STAT3	dephosphorylation
ZAP70	up-regulates	DUSP3	phosphorylation
DUSP3	“down-regulates activity”	MAPK1	dephosphorylation
DUSP3	“down-regulates activity”	Gbeta	dephosphorylation
DUSP3	“down-regulates activity”	ERK1/2	dephosphorylation
VRK3	“up-regulates activity”	DUSP3	binding
SYK	“up-regulates activity”	DUSP3	phosphorylation
ZAP70	“up-regulates activity”	DUSP3	phosphorylation

Disease & clinical

Genetic variants

Variant evidence for DUSP3: 24 ClinVar records (0 pathogenic / likely pathogenic); 6 GWAS associations.

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	1
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 26 predictions of 268):

Position(s)	Effect	Δscore	Sites
17:43769624	donor_gain	1.0000
17:43774710–43774711	donor_loss	1.0000	5
17:43774939–43774940	acceptor_loss	1.0000	5
17:43769815–43769816	acceptor_loss	0.9900	6
17:43774710	donor_loss	0.9900
17:43774939	acceptor_loss	0.9900
17:43778798–43778799	donor_loss	0.9900	4
17:43778811	donor_gain	0.9900
17:43769628	donor_gain	0.9700
17:43778309	donor_gain	0.9700

AlphaMissense

540 missense substitutions predicted likely pathogenic (of 1,224 scored), across 133 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M140	9	0.819	0.988
D92	8	0.998	1.000
S129	8	0.985	0.997
F166	8	0.981	0.999
H123	8	0.959	0.992
N61	8	0.957	0.997
F102	8	0.933	0.986
N163	8	0.931	0.990
H58	8	0.852	0.990
H70	8	0.820	0.936
F108	7	0.977	0.996
C124	7	0.972	0.997
F96	7	0.942	0.997
M69	7	0.881	0.965
E126	7	0.844	0.916
F77	7	0.832	0.962
F68	7	0.805	0.939
D164	7	0.723	0.821
G127	6	0.995	0.998
R130	6	0.992	0.998

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	2.24e-05
Ovary Serous Cystadenocarcinoma (validation)	unfavorable	0.00046
Head and Neck Squamous Cell Carcinoma (TCGA)	unfavorable	0.000882

Disease associations

OMIM: gene MIM:600183 | disease phenotypes:

GWAS associations

6 associations:

Study	Trait	p-value
GCST011348_20	High density lipoprotein cholesterol levels	2e-41
GCST006423_13	Fracture	3e-25
GCST002899_34	HDL cholesterol	1e-14
GCST002897_5	Triglycerides	8e-13
GCST003660_1	HDL cholesterol	1e-11
GCST009391_1166	Metabolite levels	8e-6

EFO canonical traits (from GWAS)

3 canonical traits:

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0010370	lysophosphatidylethanolamine 20:4 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2635 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

493 measured of 700 human assays (722 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
5-(tosylmethyl)-2-furoic acid	IC50	23 nM
3,4-Dihydroxycinnamate, XVII	IC50	24 nM
4-(phenylmethyl)-N-(4-sulfamoylphenyl)piperazine-1-carboxamide	KI	50 nM
SMR000278513	IC50	57.2 nM
4-chloranyl-N-(3,4-dihydro-2H-thiochromen-4-yl)-3-sulfamoyl-benzamide	IC50	121 nM
MLS000621468	KI	125 nM
N-[3-[(2-methoxyphenyl)sulfamoyl]-4-(1-pyrrolidinyl)phenyl]-3-methyl-2-thiophenecarboxamide	IC50	163 nM
(7Z)-3-bromo-7-[(2-chlorophenyl)methylidene]-[1,3]thiazolo[4,5]imidazo[1,2-b]pyridin-8-one	IC50	181 nM
(2E)-3-{3-[dihydroxy(oxo)–stibanyl]phenyl}prop-2-enoic acid	IC50	200 nM
4-amino-3-(4-methylphenyl)-5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-thiazole-2(3H)-thione	IC50	250 nM
cid_9512029	IC50	313 nM
1-(2,6-dichlorophenyl)-3-(2-phenylethyl)thiourea	IC50	342 nM
cid_3578672	IC50	342 nM
1-[[1-(1-phenylethyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea	IC50	343 nM
2-(5-((3-(4-(2-chlorobenzyloxy)phenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)ethanesulfonic acid	IC50	470 nM
cid_67062	IC50	485 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-(2-methoxyethyl)urea	IC50	492 nM
MLS000409155	IC50	498 nM
SMR000311544	IC50	500 nM
cid_3823393	IC50	520 nM
cid_2162931	IC50	567 nM
3-methyl-7-(3-phenylpropyl)-8-[2-(1-piperidinyl)ethylthio]purine-2,6-dione	IC50	570 nM
MLS-0437609.0002	IC50	682 nM
MLS000584539	IC50	696 nM
MLS000050448	IC50	716 nM
(4-bromophenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione	IC50	719 nM
1-(3-chloro-4-methoxyphenyl)-3-[2-(4-methyl-1-piperidinyl)ethyl]thiourea	IC50	720 nM
MLS-0109562.0001	IC50	727 nM
cid_6161440	IC50	730 nM
3-[[5-(acetyloxymethyl)-3-[(2,4-dimethoxyphenyl)carbamoyl]-8-methylpyrano[2,3-c]pyridin-2-ylidene]amino]benzoic acid	IC50	737 nM
N’-(5-chloro-2-methoxyphenyl)-N-[(1-methyl-1H-indol-3-yl)methyl]-N-(3-morpholin-4-ylpropyl)thiourea	IC50	754 nM
CHEMBL2316908	IC50	800 nM
SMR000624920	IC50	804 nM
2-((Z)-4-oxo-5-((E)-3-phenylallylidene)-2-thioxothiazolidin-3-yl)ethane-sulfonic acid	KI	809 nM
SMR000143195	IC50	810 nM
6-[(5Z)-5-(1-methyl-2-oxo-3-indolylidene)-4-oxo-2-sulfanylidene-3-thiazolidinyl]hexanoic acid	IC50	836 nM
SMR001268769	IC50	927 nM
MLS000679877	IC50	937 nM
SMR000198085	IC50	942 nM
(5-methyl-2-thiophenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione	IC50	997 nM
MLS001008494	IC50	1030 nM
N’-(4-chloro-2-methoxyphenyl)-N-[(1-methyl-1H-indol-3-yl)methyl]-N-(3-morpholin-4-ylpropyl)thiourea	IC50	1030 nM
MLS001196239	IC50	1030 nM
1-(3-propan-2-yloxypropyl)-3-(4-sulfamoylphenyl)thiourea	IC50	1080 nM
6-Chloro-7-(2-morpholin-4-yl-ethylamino)-phthalazine-5,8-dione	IC50	1100 nM
1-(3-chloro-4-methoxyphenyl)-3-[3-(1-pyrrolidinyl)propyl]thiourea	IC50	1120 nM
1-[(4-bromophenyl)carbonothioyl]-4-methylpiperazine	IC50	1140 nM
1-[(E)-(1,3-dimethylpyrazol-4-yl)methylideneamino]-3-phenyl-thiourea	IC50	1220 nM
MLS-0091940.0001	IC50	1230 nM
2,3,4,5-tetrahydroxy-6-benzo[7]annulenone	IC50	1230 nM

ChEMBL bioactivities

458 potent at pChembl≥5 of 686 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.75	IC50	18	nM	CHEMBL565795
7.19	IC50	65	nM	CHEMBL1460470
7.15	IC50	71	nM	CHEMBL567069
7.13	IC50	74	nM	CHEMBL584481
7.11	IC50	78	nM	CHEMBL565810
7.08	IC50	82.8	nM	CHEMBL1460470
6.92	IC50	121	nM	CHEMBL1460470
6.90	IC50	127	nM	CHEMBL1608642
6.84	IC50	143	nM	CHEMBL1322542
6.79	IC50	163	nM	CHEMBL1463248
6.74	IC50	181	nM	CHEMBL1448629
6.67	IC50	216	nM	CHEMBL1385949
6.66	IC50	220	nM	CHEMBL1705741
6.66	IC50	218	nM	CHEMBL1445488
6.65	IC50	226	nM	CHEMBL1393151
6.60	IC50	250	nM	CHEMBL1605172
6.58	IC50	260	nM	CHEMBL1304193
6.57	IC50	271	nM	CHEMBL1385949
6.57	IC50	270	nM	CHEMBL565371
6.51	IC50	312	nM	CHEMBL1421970
6.51	IC50	308	nM	CHEMBL1371869
6.48	IC50	331	nM	CHEMBL1608642
6.47	IC50	341	nM	CHEMBL1410244
6.47	IC50	339	nM	CHEMBL1426299
6.47	IC50	342	nM	CHEMBL1331149
6.47	IC50	342	nM	CHEMBL1408579
6.46	IC50	343	nM	CHEMBL1381413
6.46	IC50	343	nM	CHEMBL1353918
6.46	IC50	345	nM	CHEMBL1603381
6.46	IC50	347	nM	CHEMBL1408579
6.45	IC50	353	nM	CHEMBL1370165
6.44	IC50	366	nM	CHEMBL1608642
6.43	IC50	370	nM	CHEMBL1608642
6.42	IC50	382	nM	CHEMBL1445488
6.41	IC50	386	nM	CHEMBL1504939
6.40	IC50	402	nM	CHEMBL1605172
6.39	IC50	408	nM	CHEMBL1727679
6.32	IC50	480	nM	CHEMBL1536896
6.32	IC50	480	nM	CHEMBL1732016
6.31	IC50	485	nM	CHEMBL1271266
6.31	IC50	492	nM	CHEMBL1501132
6.30	IC50	500	nM	CHEMBL1540065
6.30	IC50	498	nM	CHEMBL1421470
6.29	IC50	509	nM	CHEMBL1461216
6.28	IC50	530	nM	CHEMBL1304193
6.26	IC50	549	nM	CHEMBL1445488
6.26	IC50	544	nM	CHEMBL1724282
6.25	IC50	567	nM	CHEMBL1540317
6.24	IC50	570	nM	CHEMBL1569991
6.17	IC50	680	nM	CHEMBL1608654

PubChem BioAssay actives

88 with measured affinity, of 476 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(5Z)-5-[[3-[4-[(4-chlorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	0.0180	uM
2-[(5Z)-5-[[3-[4-[(2-chlorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	0.0710	uM
2-[(5Z)-5-[[3-[4-[(2-fluorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	0.0740	uM
2-[(5Z)-4-oxo-5-[[1-phenyl-3-(4-phenylmethoxyphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	0.0780	uM
2-[(5Z)-4-oxo-5-[[1-phenyl-3-(4-piperidin-1-ylsulfonylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	0.2700	uM
(4-hydroxy-3-methoxyphenyl)-piperidin-1-ylmethanethione	1206872: Inhibition of recombinant VHR (unknown origin) using OMFP as substrate after 1 hr by fluorescence assay	ic50	0.3700	uM
6-hydroxy-3-[2-(4-phenoxyphenyl)ethynyl]-2-phenyl-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	0.8000	uM
2-[(5Z)-5-[(E)-3-phenylprop-2-enylidene]-2-sulfanylidene-1,3,4-thiadiazolidin-3-yl]ethanesulfonic acid	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	0.8090	uM
6-chloro-7-(2-morpholin-4-ylethylamino)phthalazine-5,8-dione	217196: Inhibitory Activity against Recombinant Human VHR	ic50	1.1000	uM
4-[N-[(3-chlorophenyl)methyl]-C-pentadecylcarbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	673781: Inhibition of VHR	ic50	1.4300	uM
3-hydroxy-2-(hydroxymethyl)-4-[N-[(3-methylphenyl)methyl]-C-pentadecylcarbonimidoyl]-2H-furan-5-one	1139714: Inhibition of Vaccinia H1-related phosphatase (unknown origin) by fluorescence emission assay	ic50	1.6000	uM
(E)-N-[4-(1,3-benzoxazol-2-yl)phenyl]-3-[5-(2-nitrophenyl)furan-2-yl]prop-2-enamide	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	1.7600	uM
2-[(3S)-1-[[(2R)-4-hexadecanoyl-3-hydroxy-5-oxo-2H-furan-2-yl]methoxy]-2-methyl-1-oxopentan-3-yl]oxyethyl (2R)-3-hydroxy-2-(hydroxymethyl)-5-oxo-2H-furan-4-carboxylate	593417: Inhibition of VHR	ic50	1.8000	uM
2-[(5Z)-5-[[3-(4-chlorophenyl)-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	1.8000	uM
2-[(5Z)-5-[[3-(4-methoxyphenyl)-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	1.8000	uM
(5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-sulfanylidene-1,3-thiazolidin-2-one	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	1.8600	uM
6-hydroxy-2-phenyl-3-[2-[3-(trifluoromethyl)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	1.9000	uM
2-[(5Z)-4-oxo-5-[(E)-3-phenylprop-2-enylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-phenylpropanoic acid	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	2.0100	uM
2-[4-(2,5-dimethylpyrrol-1-yl)phenyl]sulfanylacetic acid	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	2.0900	uM
6-hydroxy-2-phenyl-3-[2-[4-(trifluoromethoxy)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	2.1000	uM
2-[(5Z)-5-[[3-(4-morpholin-4-ylsulfonylphenyl)-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	2.4000	uM
ethyl 5-(4-bromophenyl)-4,6-dioxo-2H-pyrrolo[3,4-c]pyrazole-3-carboxylate	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	2.6400	uM
3-hydroxy-2-(hydroxymethyl)-4-[N-[(4-methylphenyl)methyl]-C-pentadecylcarbonimidoyl]-2H-furan-5-one	673781: Inhibition of VHR	ic50	2.6800	uM
N-(4-methoxy-1,3-benzothiazol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine	1206872: Inhibition of recombinant VHR (unknown origin) using OMFP as substrate after 1 hr by fluorescence assay	ic50	2.6800	uM
1-dibenzofuran-3-yl-3-naphthalen-1-ylthiourea	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	2.9400	uM
1,4-dimethoxyanthracene-9,10-dione	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	3.0700	uM
2-[(5Z)-5-[[3-(4-methylphenyl)-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443928: Inhibition of recombinant vaccina H1-related phosphatase	ic50	3.1000	uM
2-[(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	3.1300	uM
(5Z)-5-[[5-(2-bromo-4,5-dimethylphenyl)furan-2-yl]methylidene]-2-sulfanylideneimidazolidin-4-one	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	3.1900	uM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182551: Inhibition of VHR (unknown origin)	ic50	3.2000	uM
1-(3-chlorophenyl)-6-hydroxy-5-[(E)-pyrrol-2-ylidenemethyl]-2-sulfanylidenepyrimidin-4-one	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	3.4900	uM
4-[N-[(4-chlorophenyl)methyl]-C-pentadecylcarbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	673781: Inhibition of VHR	ic50	3.6300	uM
N-(4-fluoro-1,3-benzothiazol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine	1206872: Inhibition of recombinant VHR (unknown origin) using OMFP as substrate after 1 hr by fluorescence assay	ic50	3.7000	uM
4-[5-[(E)-(2-amino-3,7-dicyano-4,6-dimethylcyclopenta[b]pyridin-5-ylidene)methyl]furan-2-yl]-2-chlorobenzoic acid	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	3.8700	uM
3-[2-(2,4-difluorophenyl)ethynyl]-6-hydroxy-2-phenyl-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	3.9000	uM
6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione	217196: Inhibitory Activity against Recombinant Human VHR	ic50	4.0000	uM
[3-[3-[(3S)-3-(methylcarbamoyl)-7-(sulfoamino)-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropyl]phenyl]sulfamic acid	262288: Inhibition of VHR	ic50	4.0000	uM
(3-benzoylphenyl) 2-[(2R)-4-hexadecanoyl-3-hydroxy-5-oxo-2H-furan-2-yl]acetate	217197: Inhibitory activity against vaccinia VH1-related phosphatase (VHR)	ic50	4.0000	uM
3-[2-(3-fluorophenyl)ethynyl]-6-hydroxy-2-phenyl-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	4.1000	uM
2-[4-[(Z)-[5-(4-chlorophenyl)-6-ethoxycarbonyl-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	569642: Inhibition of recombinant VHR expressed in Escherichia coli	ic50	4.2000	uM
(5E)-5-[(5-iodofuran-2-yl)methylidene]-1-(4-methoxyphenyl)-2-sulfanylidene-1,3-diazinane-4,6-dione	443921: Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies	ki	4.4400	uM
4-[C-[4-[4-[(4-chlorophenyl)methoxy]phenyl]butyl]-N-[(3-methylphenyl)methyl]carbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	1139709: Inhibition of Vaccinia H1-related phosphatase (unknown origin) by fluorescence emission assay in presence of 0.001% NP-40	ic50	4.6000	uM
(4-benzoylphenyl) 2-[(2R)-4-hexadecanoyl-3-hydroxy-5-oxo-2H-furan-2-yl]acetate	217197: Inhibitory activity against vaccinia VH1-related phosphatase (VHR)	ic50	4.6000	uM
4-[N-[(3-fluorophenyl)methyl]-C-pentadecylcarbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	673781: Inhibition of VHR	ic50	4.6900	uM
[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl] 2-[(2R)-4-hexadecanoyl-3-hydroxy-5-oxo-2H-furan-2-yl]acetate	217197: Inhibitory activity against vaccinia VH1-related phosphatase (VHR)	ic50	4.7000	uM
(2Z)-2-[1-[5-(1H-pyrrol-2-yl)furan-2-yl]ethylidene]pyrrole	1799614: Phosphatase Inhibition Assay from Article 10.1002/cbic.200400135: “The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors.”	ic50	4.9000	uM
6-hydroxy-2-phenyl-3-(2-phenylethynyl)-1-benzofuran-5-carboxylic acid	725032: Inhibition of VHR (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	5.0000	uM
methyl 5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpyridine-2-carboxylate	217196: Inhibitory Activity against Recombinant Human VHR	ic50	5.1000	uM
4-[N-[[3-(dimethylamino)phenyl]methyl]-C-pentadecylcarbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	673781: Inhibition of VHR	ic50	5.1300	uM
4-[N-[[2-(dimethylamino)phenyl]methyl]-C-pentadecylcarbonimidoyl]-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one	673781: Inhibition of VHR	ic50	5.1900	uM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	6
Benzo(a)pyrene	affects methylation, increases expression	3
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	increases abundance, decreases expression	2
methylmercuric chloride	increases expression	1
bisphenol A	increases expression	1
sodium arsenite	increases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
nutlin 3	increases expression	1
ICG 001	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	increases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	increases expression	1
Gefitinib	affects response to substance	1
Sorafenib	affects cotreatment, increases expression	1
Resveratrol	decreases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases methylation	1
Cadmium	increases expression	1
Chelating Agents	increases expression, affects binding	1
Cisplatin	affects expression	1
Coal	decreases expression, increases abundance	1
Copper	affects binding, increases expression	1

ChEMBL screening assays

101 unique, capped per target: 95 binding, 5 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1034380	Binding	Inhibition of VHR expressed in Escherichia coli BL21(DE9)	Bitungolides A-F, new polyketides from the Indonesian sponge Theonella cf. swinhoei. — *J Nat Prod*
CHEMBL1738089	Functional	PUBCHEM_BIOASSAY: SAR VHR1 Fluorescent Assay for In Vitro dose response studies. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1654, AID1661, AID1878, AID1992, AID2004, AID2070, AID2085]	PubChem BioAssay data set
CHEMBL4626312	ADMET	Inhibition of VHR (unknown origin) expressed in Escherichia coli BL21 using p-nitrophenyl phosphate as substrate measured after 30 mins by UV-vis spectrophotometric method	Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. — *J Med Chem*

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7P2	Ubigene A-549 DUSP3 KO	Cancer cell line	Male
CVCL_D8KH	Ubigene HCT 116 DUSP3 KO	Cancer cell line	Male
CVCL_D9DT	Ubigene HEK293 DUSP3 KO	Transformed cell line	Female
CVCL_E0C4	Ubigene HeLa DUSP3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for DUSP3 across ~30M SureChEMBL compounds — explore on Sugi Predict.